Date: 2012-02-22
Type of information: Licensing agreement
Compound: colorectal cancer tissue biomarkers
Company: Oxford Gene Technology (UK) Inven2 (Norway) University of Oslo (Norway)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: colorectal cancer
Details: * On February22, 2012, Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine,has announced that it has entered into an exclusive licensing agreement with Inven2, the technology transfer office at Oslo University Hospital (OUS) and University of Oslo (UiO), for 12 highly promising colorectal cancer tissue biomarkers.
The exclusive license allows OGT to commercialise any resulting test developed using these biomarkers and to sublicense the markers to other parties. The DNA methylation biomarkers were developed in the laboratory of Professor Ragnhild A. Lothe, in the department of Cancer Prevention, the Norwegian Radium Hospital, part of the Oslo University Hospital.
OGT has validated the results obtained in Professor Lothe’s laboratory showing sensitivity of 93% and specificity of 90% when using tissue biopsies. Further work investigating the efficacy of these biomarkers in blood and faecal samples is ongoing.
Financial terms:
Latest news:
